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AH

:   alcoholic hepatitis

ALD

:   alcoholic liver disease

AST

:   aspartate aminotransferase

CI

:   confidence interval

OR

:   odds ratio

PNPLA3

:   patatin‐like phospholipase domain‐containing protein 3

TREAT

:   Translational Research and Evolving Alcoholic Hepatitis Treatment

Introduction {#hep41123-sec-0001}
============

Alcoholic liver disease (ALD) comprises a spectrum of disorders in individuals with acute and chronic alcohol consumption, ranging from alcoholic steatosis to alcoholic hepatitis (AH) and cirrhosis.[1](#hep41123-bib-0001){ref-type="ref"} AH is the most florid manifestation of ALD and is associated with a high mortality.[1](#hep41123-bib-0001){ref-type="ref"} ALD only develops in a subset of subjects with excessive alcohol use, suggesting that other factors in addition to alcohol are involved in disease pathogenesis.[2](#hep41123-bib-0002){ref-type="ref"} A recent meta‐analysis showed the patatin‐like phospholipase domain‐containing protein 3 (*PNPLA3)* variant (rs738409, C\>G) as the main genetic determinant of alcoholic cirrhosis.[3](#hep41123-bib-0003){ref-type="ref"} In our Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) consortium study (TREAT001; NCT\#02172898),[4](#hep41123-bib-0004){ref-type="ref"} we found a higher overall allelic frequency of *PNPLA3* rs738409 among AH cases when compared to heavy drinkers without liver disease (0.34 versus 0.22; *P* = 0.007),[4](#hep41123-bib-0004){ref-type="ref"} with *PNPLA3* G/C and G/G genotypes conferring an increased risk for AH among heavy drinkers.[5](#hep41123-bib-0005){ref-type="ref"}

This genetic variant, however, does not explain all the risk for AH, suggesting that other genetic or environmental factors play a role. Coffee is one of the most commonly consumed beverages, and coffee drinking was inversely associated with nonalcoholic and alcoholic liver cirrhosis.[5](#hep41123-bib-0005){ref-type="ref"}, [6](#hep41123-bib-0006){ref-type="ref"}, [7](#hep41123-bib-0007){ref-type="ref"} Coffee improves serum transaminases and is inversely associated with the severity of steatohepatitis in patients with nonalcoholic fatty liver disease.[8](#hep41123-bib-0008){ref-type="ref"} The aim of the present study was to investigate the role of coffee drinking and its association with *PNPLA3* rs738409 as risk factors for AH.

Methods {#hep41123-sec-0002}
=======

STUDY COHORT {#hep41123-sec-0003}
------------

The analyses were performed on subjects who were recruited as part of the TREAT001 study. Detailed data were collected on demographics, alcohol use, regular coffee consumption (defined as subjects who drank ≥4 times per week for 5 years), and laboratory values, as described.[4](#hep41123-bib-0004){ref-type="ref"} We used the following criteria for AH diagnosis: (1) average daily ethanol consumption of \>40 and \>60 grams/day for women and men, respectively; (2) consuming alcohol for at least 6 months and within the 6 weeks before enrollment; and (3) total bilirubin \>2 mg/dL and aspartate aminotransferase (AST) \>50 U/L at admission.[4](#hep41123-bib-0004){ref-type="ref"} Controls were recruited from the Fairbanks Drug and Alcohol Treatment Center (Indianapolis, IN). They were at least 21 years old without underlying medical illnesses, such as chronic obstructive pulmonary disease, congestive heart failure, diabetes, cancer, or chronic renal failure. These subjects had normal results for AST, alanine aminotransferase, total bilirubin, albumin, platelet count, and international normalized ratio and had no past history of jaundice or signs of portal hypertension.[4](#hep41123-bib-0004){ref-type="ref"}

GENOTYPING FOR *PNPLA3* {#hep41123-sec-0004}
-----------------------

Determination of *PNPLA3* rs738409 (C\>G) polymorphism was performed using the Illumina MEGA BeadChip (Illumina Inc., San Diego, CA) at the Mammalian Genotyping Core, University of North Carolina at Chapel Hill.

STATISTICAL ANALYSIS {#hep41123-sec-0005}
--------------------

Basic descriptive statistics, including mean, SD, and frequencies (percentages) were used to characterize the data set. The chi‐square and Student *t* tests were used for comparison between groups for categorical and continuous variables, respectively. We examined the relation of AH with variables of interest by first comparing the prevalence of AH among the levels of these variables. To further study the strength and form of association between coffee consumption and PNPLA3 gene status, we employed multivariable logistic regression modeling that controlled for the potential effects of other variables related to AH. The modeling procedure was conducted as follows: First, the variables PNPLA3, coffee consumption, body mass index, age, and sex were tested in univariate models (race was not included because all patients with PNPLA3 information were Caucasian) with AH status at baseline as the outcome. Clinical and laboratory results were not included as potential adjustments because it is well known that these variables are associated with AH status and this was not our primary focus. Variables for which the univariate *P* satisfied *P* \< 0.20 were considered for inclusion in the final multivariable model. Next, all possible models composed of combinations of main effects from the screened variables were fit, and the model with the minimum Akaike information criterion was selected as optimal.[9](#hep41123-bib-0009){ref-type="ref"} After selection of the optimal model, an interaction term between PNPLA3 and coffee consumption was added to assess evidence for its inclusion in the final model. The resulting model was then used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). A *P* value of \<0.05 was considered statistically significant in the final multivariable model. All analyses were performed with SAS software version 9.3 (Cary, NC).

Results {#hep41123-sec-0006}
=======

CLINICAL CHARACTERISTICS {#hep41123-sec-0007}
------------------------

During the study period from May 2013 to May 2016, 189 cases with AH and 150 controls were prospectively enrolled. The detailed demographic and clinical characteristics of the study cohort are summarized in Table [1](#hep41123-tbl-0001){ref-type="table-wrap"}. Among regular coffee drinkers, the average duration of regular coffee consumption for controls and cases with AH was 26.7 ± 12.6 and 26.3 ± 13.8 years, respectively. Controls drank ∼3.4 ± 2.1 (mean ± SD) cups, while cases with AH consumed ∼2.6 ± 3.0 cups daily.

###### 

BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY COHORT

  ----------------------------------------------------------------------------------------------------------------------------------------
  Variables                                       Controls\      AH Cases\       *P* Value                                          
                                                  (n = 150)      (n = 189)                                                          
  ----------------------------------------------- -------------- --------------- ----------- ------------ ------------ ------------ ------
  Age (years)                                     44.2 ± 12.3    46.7 ± 11.0     NS                                                 

  Men, n (%)                                      95 (63.3%)     113 (59.8%)     NS                                                 

  Race, Caucasian, n (%)                          126 (84.0%)    165 (87.3%)     NS                                                 

  BMI (kg/m^2^)                                   28.6 ± 7.1     29.3 ± 8.3      NS                                                 

  Regular coffee consumption, n (%)               65 (43.3%)     38 (20.4%)      \<0.0001                                           

  *PNPLA3*                                        CC             GC              GG          CC           GC           GG           0.03

                                                  57 (61.3%)     32 (34.4%)      4 (4.3%)    39 (43.3%)   41 (45.6%)   10 (11.1%)   

  WBC (×10^3^ cells/mm^3^)                        7.2 ± 2.6      11.4 ± 7.9      \<0.0001                                           

  Hemoglobin (g/dL)                               13.0 ± 2.1     10.1 ± 2.0      \<0.0001                                           

  Platelet counts (×10^3^ cells/mm^3^)            244.2 ± 71.8   144.2 ± 85.7    \<0.0001                                           

  Total bilirubin (mg/dL)                         0.5 ± 0.3      13.9 ± 11.5     \<0.0001                                           

  INR                                             1.0 ± 0.2      1.8 ± 0.5       \<0.0001                                           

  AST (U/L)                                       27.7 ± 9.2     140.1 ± 88.2    \<0.0001                                           

  ALT (U/L)                                       25.8 ± 10.4    62.9 ± 65.8     \<0.0001                                           

  Alkaline phosphatase (U/L)                      76.1 ± 31.3    193.6 ± 138.1   \<0.0001                                           

  Albumin (g/dL)                                  3.9 ± 0.6      2.8 ± 0.7       \<0.0001                                           

  Total protein (g/dL)                            6.5 ± 0.8      6.1 ± 0.9       \<0.0001                                           

  Creatinine (mg/dL)                              0.9 ± 0.3      1.0 ± 0.9       NS                                                 

  MELD Scores                                     7.1 ± 2.3      22.1 ± 7.0      \<0.0001                                           

  Severity of liver diseases (MELD \>20), n (%)   0              110 (58%)       NA                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; INR, international normalized ratio; MELD, Model for End‐Stage Liver Disease; WBC, white blood count.

MULTIVARIATE LOGISTIC REGRESSION MODELING {#hep41123-sec-0008}
-----------------------------------------

All patient characteristic variables, namely age, body mass index, and sex, did not pass the univariate screen for inclusion into the final multivariable model. Only PNPLA3 and coffee consumption exhibited univariate *P* values less than 0.20 (*P* = 0.0156 and *P* = 0.0036, respectively; Table [2](#hep41123-tbl-0002){ref-type="table-wrap"}). The multivariable logistic regression model that included only the main effects for coffee consumption and PNPLA3 status was selected as optimal and provided a better fit than the multivariable logistic regression model that included the main effects and an interaction (Akaike information criterion, 245.78 versus 247.75, respectively). The results implied by the final multivariable model are summarized in the following subsections.

###### 

UNIVARIATE MODEL RESULTS AND MULTIVARIABLE MODEL ESTIMATES (*PNPLA3* VARIANT AND COFFEE CONSUMPTION AND THEIR ASSOCIATION WITH AH)

  -------------------------------------------------------------------------------------------------
  Variable                          Estimate   Standard\   *P* Value   Odds Ratio   95% CI   
                                               Error                                         
  --------------------------------- ---------- ----------- ----------- ------------ -------- ------
  Univariate Models                                                                          

  Age                               0.02       0.01        0.21        1.01         0.99     1.04

  Body mass index                   0.007      0.02        0.70        1.00         0.97     1.05

  Sex (female vs male)              --0.08     0.30        0.78        0.92         0.51     1.67

  *PNPLA3* genotype (GG/GC vs CC)   0.73       0.30        0.01        2.07         1.15     3.74

  Coffee consumption                --0.93     0.32        0.004       0.39         0.21     0.74

  Multivariable Model                                                                        

  *PNPLA3* variant (GC/GG vs CC)    0.69       0.31        0.02        2.00         1.09     3.65

  Coffee consumption\               --0.90     0.33        0.005       0.41         0.21     0.77
  (Yes vs No)                                                                                
  -------------------------------------------------------------------------------------------------

*PNPLA3* POLYMORPHISM IN AH AND CONTROLS {#hep41123-sec-0009}
----------------------------------------

The distribution of the *PNPLA3* CC, CG, and GG genotypes[10](#hep41123-bib-0010){ref-type="ref"} and its allelic frequencies were determined in a subset of 90 cases with AH and 93 controls of European ancestry.[4](#hep41123-bib-0004){ref-type="ref"} The overall minor allele frequency of *PNPLA3* rs 738409 was 0.34 and 0.22 for AH cases and controls, respectively. We found evidence that the distribution of PNPLA3 varied by AH case status. Particularly, it seems that a higher percentage of AH cases have at least one G variant (*P* = 0.0301; Table [1](#hep41123-tbl-0001){ref-type="table-wrap"}). In the multivariable analyses, the presence of the GG/GC allele was associated with increased prevalence of AH (OR, 2.00; 95% CI, 1.09‐3.65; Table [2](#hep41123-tbl-0002){ref-type="table-wrap"}) after adjusting for coffee consumption.[4](#hep41123-bib-0004){ref-type="ref"}

COFFEE CONSUMPTION AND AH {#hep41123-sec-0010}
-------------------------

We found that the prevalence of regular coffee consumption was significantly lower in patients with AH when compared to controls (20% versus 43%; *P \<* 0.0001; Table [1](#hep41123-tbl-0001){ref-type="table-wrap"}). The association persisted in the multivariable logistic regression analysis after adjusting for *PNPLA3* polymorphism (OR, 0.41; 95% CI, 0.21‐0.77; Table [2](#hep41123-tbl-0002){ref-type="table-wrap"}).

INTERACTION BETWEEN *PNPLA3* POLYMORPHISM AND COFFEE CONSUMPTION AND THE RISK FOR AH {#hep41123-sec-0011}
------------------------------------------------------------------------------------

We investigated the relationship between *PNPLA3* polymorphism and coffee consumption and the prevalence of AH among the pooled cohort of 183 heavy drinkers with and without AH. Among heavy drinkers who carried the *PNPLA3* CC genotype and were regular coffee drinkers, the prevalence of AH was 27%. The prevalence estimate increased to 86% for nonregular coffee drinkers with the *PNPLA3* GG genotype; however, multivariable logistic regression modeling showed that there was insufficient evidence for inclusion of an interaction effect between PNPLA3 and coffee consumption, after adjusting for relevant baseline characteristics.

Discussion {#hep41123-sec-0012}
==========

ALD, a major complication of excessive alcohol use, is one of the leading causes of chronic liver disease with substantial morbidity and mortality.[11](#hep41123-bib-0011){ref-type="ref"} Continued drinking can lead to alcoholic cirrhosis in up to 15%‐20% of excessive drinkers in their lifetime,[12](#hep41123-bib-0012){ref-type="ref"} suggesting that other factors in addition to excessive alcohol drinking are involved in progression. We found an important gene (*PNPLA3*) and environmental (coffee drinking) effect and an association with AH among those who consume alcohol heavily. Although previous studies have shown independent relationships between *PNPLA3* variants[3](#hep41123-bib-0003){ref-type="ref"} and coffee drinking and various liver diseases,[8](#hep41123-bib-0008){ref-type="ref"}, [13](#hep41123-bib-0013){ref-type="ref"} to our knowledge this is the first report to investigate them together as risk factors for AH.

The *PNPLA3* gene is located on the long arm of chromosome 22.[14](#hep41123-bib-0014){ref-type="ref"} *PNPLA3* rs738409 (C\>G) has been shown to be associated with alcoholic cirrhosis,[15](#hep41123-bib-0015){ref-type="ref"}, [16](#hep41123-bib-0016){ref-type="ref"}, [17](#hep41123-bib-0017){ref-type="ref"} and we have found that those patients with the GG/GC allele are associated with AH. Our observation that coffee drinking may exert a protective effect against AH is interesting and deserves further discussion. Several studies have found an inverse relationship between coffee consumption and levels of gamma glutaryltransferase.[18](#hep41123-bib-0018){ref-type="ref"}, [19](#hep41123-bib-0019){ref-type="ref"} In patients with chronic hepatitis C infection, higher coffee consumption was associated with less steatosis on liver biopsy, lower serum AST/alanine aminotransferase ratio, and lower alpha‐fetoprotein and insulin.[20](#hep41123-bib-0020){ref-type="ref"} Increasing coffee intake was associated with a decrease in adverse outcomes, such as ascites, liver disease‐related death, and complications of portal hypertensions, or a ≥2‐point increase in the Ishak fibrosis score during follow‐up biopsies in patients with hepatitis C infection.[20](#hep41123-bib-0020){ref-type="ref"} Mechanistically, it was shown that caffeine, the main component found in coffee, has anti‐inflammatory properties.[13](#hep41123-bib-0013){ref-type="ref"}, [21](#hep41123-bib-0021){ref-type="ref"} Treatment with caffeine significantly attenuated the increase in serum aminotransferases and ameliorated hepatocyte damage and hepatic steatosis through inhibition of lipogenic genes in ethanol‐fed mice.[21](#hep41123-bib-0021){ref-type="ref"} Further, caffeine reduces intrahepatic lipid content and stimulates β‐oxidation in hepatocytes by an autophagy--lysosomal pathway.[22](#hep41123-bib-0022){ref-type="ref"} In mice fed a high‐fat diet, caffeine markedly reduced steatosis by inducing autophagy and lipid uptake in lysosomes.[22](#hep41123-bib-0022){ref-type="ref"} Caffeine can also inhibit the production of tumor necrosis factor α and reactive oxygen species by Kupffer cells.[21](#hep41123-bib-0021){ref-type="ref"} Lastly, caffeine\'s protective mechanism may be mediated through its antagonistic effect on adenosine receptors and thus inhibition of collagen synthesis by hepatic stellate cells.[23](#hep41123-bib-0023){ref-type="ref"} While caffeine might be the mechanistically important component of coffee, some studies have suggested that the protective effect of coffee against hepatic injury may be secondary to noncaffeine‐mediated mechanisms,[13](#hep41123-bib-0013){ref-type="ref"}, [24](#hep41123-bib-0024){ref-type="ref"} as demonstrated by the protective effects of decaffeinated coffee. However, the evidence is weaker overall for decaffeinated than for regular coffee.[13](#hep41123-bib-0013){ref-type="ref"}

Our results suggest that coffee drinking favorably modifies the adverse effects of *PNPLA3* minor alleles among heavy drinkers, but the mechanistic basis for this phenomenon is unclear. PNPLA3 plays a role in the hydrolysis of glycerolipids, and its variant leads to a loss of this function.[14](#hep41123-bib-0014){ref-type="ref"} The *PNPLA3* variant also is associated with the presence of large hepatic lipid droplets, and the accumulation of inactive PNPLA3 on lipid droplets may cause hepatic triglyceride accumulation.[25](#hep41123-bib-0025){ref-type="ref"} It is plausible that heavy drinkers with the *PNPLA3* variant who are not regular coffee drinkers may have increased lipogenesis; however, they may not be able to effectively export the increase in the amount of lipid leading to subsequent liver injury. This hypothesis warrants further mechanistic investigation.

Our study has several strengths and limitations. The strengths are the prospective study design. We also included a cohort of heavy drinker controls without a history or laboratory evidence of liver disease. We acknowledge several limitations of our study. First, the self‐reported questionnaire was determined at baseline at the time of enrollment, and we did not capture long‐term or lifetime coffee consumption. Additionally, we do not have information on decaffeinated coffee consumption in our study cohort. Second, the diagnosis of AH was based on clinical criteria as reported by the TREAT consortium[4](#hep41123-bib-0004){ref-type="ref"} instead of using liver biopsy. Given the lack of histopathologic finding, we cannot rule out the possibilities that the *PNPLA3* GG variant may be associated with underlying alcoholic cirrhosis rather than AH. Third, our sample size is relatively small. Despite this limitation, we found a higher prevalence of those with the GG variant in AH subjects.

In conclusion, we found a higher prevalence of AH among heavy drinkers with the *PNPLA3* GG and GC genotypes, regardless of coffee consumption status, and a higher prevalence of AH among heavy drinkers who are not regular coffee drinkers, regardless of PNPLA3 status. We recommend that our observations be confirmed by other investigators and that *in vitro* and *in vivo* experiments be undertaken to further explore the interaction between *PNPLA3* variants and coffee drinking and the risk for ALD.
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